In addition to his clinical practice and participation in immunotherapy-based clinical trials, Dr. Borghaei is the principal investigator (PI) of a laboratory that develops new monoclonal antibodies and novel immune-modulating drugs, with the aim of bringing these approaches to the clinic. He served as the PI of a phase III randomized study that proved the effectiveness of nivolumab in the treatment of patients with advanced non-squamous non-small cell lung cancer after progression on prior chemotherapy. This work led to the approval of nivolumab, one of the first immunotherapy-based drugs to be approved for lung cancer in this setting.

Dr. Borghaei is a member of the thoracic core committee at Eastern Cooperative Oncology Group (ECOG) and, until recently, was a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer panel. He is the recipient of an American Society of Clinical Oncology (ASCO) Young Investigator Award and an ASCO Career Development Award. Dr. Borghaei is a long-standing member of ASCO, AACR, IASLC, SITC and ECOG thoracic committee.

Dr. Borghaei has been a recipient of the Robert Krigel Memorial Award for Teaching Excellence from Fox Chase Cancer Center, ASCO’s Young Investigator Award and the Career Development Award from ASCO. His work has been published in The New England Journal of Medicine, Journal of Clinical Oncology, The Lancet Oncology, Leukemia Research, Journal of Thoracic Oncology, Clinical Cancer Research, Clinical Lung Cancer, and Journal of the National Comprehensive Cancer Network.